Acrux Limited (AU:ACR) has released an update.
Acrux Limited, an Australia-based specialty pharma company, has released its Appendix 4G and Corporate Governance Statement for the financial year ending 30 June 2024, confirming adherence to ASX Corporate Governance Council recommendations. The documents, endorsed by the Board of Directors, provide transparency regarding Acrux’s governance practices and are available on the company’s website for investor review. Acrux continues to focus on developing and commercializing topical pharmaceutical products, with significant progress in the U.S. market.
For further insights into AU:ACR stock, check out TipRanks’ Stock Analysis page.
